New strategies in GVHD prophylaxis

Bone Marrow Transplantation

Volumn 25, Issue , 2000, Pages S16-S19

  Kiehl, M G ^a   Shipkova, M ^b   Basara, N ^a   Blau, W I ^a   Fauser, A A ^a  

^a BMT Unit   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplantation; Mycophenolic acid; Prophylaxis

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS;

ACUTE DISEASE; ADULT; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LEUKEMIA; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES;

EID: 0033918852     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702346     Document Type: Article

References (27)

1. Krenger W, Ferrara JL. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res 1996; 15: 50-73.
2. Krenger W, Ferrara JL. Dysregulation of cytokines during graft-versus-host disease. J Hematother 1996; 5: 3-14.
3. Tanaka J, Imamura M, Kasai M et al. Cytokine gene expression in peripheral blood mononuclear cells during graftversus-host disease after allogeneic bone marrow transplantation. Br J Haematol 1993; 85: 558-565.
4. Chang DM, Wang CJ, Kuo SY, Lai JH. Cell surface markers and circulating cytokines in graft versus host disease. Immunol Invest 1999; 28: 77-86.
5. Woo SB, Lee SJ, Schubert MM. Graft-versus-host disease. Crit Rev Oral Biol Med 1997; 8: 201-216.
6. Frassoni F, Labopin M, Gluckman E et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time-a report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 13-18.
7. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764.
8. Byrne JL, Stainer C, Hyde H et al. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Bone Marrow Transplant 1998; 22: 541-545.
9. Zikos P, Van Lint MT, Frassoni F et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood 1998; 91: 3503-3508.
10. Zikos P, Van Lint MT, Lamparelli T et al. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica 1998; 83: 896-903.
11. Michallet M, Perrin MC, Belhabri A et al. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 145-150.
12. Deeg HJ, Lin D, Leisenring W et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graftversus-host disease: a prospective, randomized trial. Blood 1997; 89: 3880-3887.
13. Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92: 4581-4590.
14. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versushost disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
15. Jain AB, Hamad I, Rakela J et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 1998; 66: 1395-1398.
16. Grinyo JM, Gil-Vernet S, Seron D et al. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft. Nephrol Dial Transplant 1998; 13: 2601-2604.
17. Shapiro R, Jordan ML, Scantlebury VP et al. A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol 1998; 160: 1982-1985.
18. Basara N, Blau IW, Kiehl MG et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant Proc 1998; 30: 4087-4089.
19. Przepiorka D, Weisdorf D, Martin P et al. Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
20. Weber LT, Shipkova M, Lamersdorf T et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. Ger-man Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998; 9: 1511-1520.
21. Shipkova M, Niedmann PD, Armstrong VW et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 1998; 44: 1481-1488.
22. Brown RA, Adkins D, Khoury H et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J Clin Oncol 1999; 17: 806-812.
23. Basara N, Blau IW, Römer E et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22: 61-65.
24. Bornhauser M, Schuler U, Porksen G et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1998; 67: 499-504.
25. Cahn JY, Deconinck E, Tiberghien P et al. Low dose T-cell lymphocyte infusion combined with marrow T-cell depletion as prophylaxis of acute graft vs host disease for HLA identical sibling bone marrow transplantation. Hematol Cell Ther 1999; 41: 31-37.
26. Peters C, Minkov M, Gadner H et al. Proposal for standard recommendations for prophylaxis of graft-versus-host disease in children. European Group for Blood and Marrow Transplantation (EBMT) Working Party Paediatric Diseases and the International Study Committee of the BFM family-subcommittee Bone Marrow Transplantation (IBFM-STG). Bone Marrow Transplant 1998; 21: S57-S60.
27. Storb R, Pepe M, Anasetti C et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037-1045.